While China has become a key country for global clinical trials, navigating regulatory complexities and ensuring data ...

Leading pharmaceutical companies, including Dr Reddy's, Sun Pharma, Cipla, Mankind Pharma, and Natco Pharma, among others, ...

Another company involved in using AI to repurpose failed drugs – as well as drugs that have already been approved – is ...

Tv Therapeutics (NASDAQ:VTVT) said on Monday that the U.S. FDA has lifted the clinical hold on cadisegliatin's clinical trial ...

An indigenously developed gene therapy for specific blood cancers has shown a 73 per cent response rate among patients in ...

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to ...

AbbVie has reported analysis from a Phase III trial that assessed Elahere against chemotherapy for platinum-resistant ovarian ...

Press release PEP-Therapy receives FDA Orphan Drug Designation for PEP-010for treatment of Pancreatic Cancer Paris (France), March 17, 2025 – PEP-Therapy, a clinical-stage biotechnology company ...

Cadisegliatin, which was paused in the third phase of its CATT1 trial, is taken orally and is designed to target the liver specifically and aims to treat diabetes by improving blood sugar control. VTv ...

The study looked at patients with leukaemia, which occurs in bone marrow, and lymphoma, which affects the lymphatic system.

Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral ...

Shore Capital, which covers hVIVO, sees plenty of upside. The broker notes that the company’s cash generation, revenue visibility, and profitability make it an outlier in healthcare, where many firms ...